Medication info

Sabetec Tablet 5/20 Milligrams

Prescription medicationTabletOralExpired
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletAmlodipine Besylate›6.94mg / 1 tablet
Manufacturer / importer
Kukje Pharmaceutical Co., Ltd.
Appearance
White round film-coated tablet
Packaging
30 tablets (10 tablets/PTP × 3)
Approval status
Expired

MFDS item code 201405081 · Approved 2014.10.31

This product's status changed to Expired on 2024.10.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Administer 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this drug, it is recommended that the dosage of the individual components (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using an individual component, switching directly to this drug may be considered. The maximum dosage of this drug is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dosage at intervals of 2 weeks or more, taking the patient's blood pressure response into account. The recommended dosages are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dosage of olmesartan medoxomil in patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dosage while closely monitoring their condition. ∘Patients with hepatic impairment: Use caution when administering to patients with mild or moderate hepatic impairment. The recommended initial dosage of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dosage is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. Do not administer this drug to patients with severe hepatic impairment. (See section 2. Patients in whom this drug should not be administered, under Precautions for Use.) ∘Older adults: In general, initiate treatment at a low dosage. When adjusting the dosage, take the patient's renal or cardiac function and comorbidities into consideration. Blood pressure should be monitored more frequently and closely in older adults.
Child dose
Safety and efficacy have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Kukje Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used to effectively lower blood pressure in patients with essential hypertension who are inadequately controlled with amlodipine or olmesartan medoxomil monotherapy. By doing so, it helps reduce the risk of cardiovascular complications and improves the overall health of patients.

How to take

Adult dose

Administer 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this drug, it is recommended that the dosage of the individual components (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using an individual component, switching directly to this drug may be considered. The maximum dosage of this drug is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dosage at intervals of 2 weeks or more, taking the patient's blood pressure response into account. The recommended dosages are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dosage of olmesartan medoxomil in patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dosage while closely monitoring their condition. ∘Patients with hepatic impairment: Use caution when administering to patients with mild or moderate hepatic impairment. The recommended initial dosage of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dosage is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. Do not administer this drug to patients with severe hepatic impairment. (See section 2. Patients in whom this drug should not be administered, under Precautions for Use.) ∘Older adults: In general, initiate treatment at a low dosage. When adjusting the dosage, take the patient's renal or cardiac function and comorbidities into consideration. Blood pressure should be monitored more frequently and closely in older adults.

Child dose

Safety and efficacy have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. It should not be taken in cases of allergy to the active ingredients or similar substances, during pregnancy or breastfeeding, severe liver impairment, aortic stenosis, biliary obstruction, in patients undergoing renal dialysis, patients in a state of shock, or in certain diabetic patients. Close monitoring is essential when starting treatment in patients with fluid or salt depletion, as hypotension may occur; if hypotension develops, appropriate measures should be taken. Rapid vasodilation may cause hypotension, so patients with aortic stenosis should be particularly cautious. Patients with severe obstructive coronary artery disease may have an increased risk of angina or myocardial infarction upon initial dosing or dosage increase. Patients with heart failure should use it cautiously, and patients with impaired kidney function may also experience changes in renal function, requiring caution. Patients with decreased liver function should be cautious as the medication may remain in the body for a prolonged period. Side effects such as dizziness, headache, hypotension, nausea, rash, swelling, etc., may occur during the course of treatment, and any unusual symptoms should be reported to healthcare professionals. Grapefruit juice should be avoided as it may excessively increase the effects of the medication. It is generally advised not to use this medication during pregnancy, and if planning pregnancy or if pregnancy is confirmed, consultation with healthcare professionals is mandatory. Breastfeeding mothers should discontinue either breastfeeding or the medication, as it can be transferred via breast milk. Safety and efficacy for children under 18 years of age have not been established, and it is best to avoid administering this medication to them. Elderly patients may have decreased renal and liver function, so starting at a lower dose and careful monitoring is advised. Overdose may result in hypotension and arrhythmias; immediate treatment at a hospital is required, and blood pressure-raising treatment may be necessary.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • hypoesthesia
  • syncope
Show 93 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • polyuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • dependent edema
  • fatigue
  • weakness
  • facial swelling
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin
  • decreased hematocrit
  • cholelithiasis
  • female breast neoplasm
  • worsening of cerebral infarction
  • gum bleeding
  • orthostatic dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • rhinorrhea
  • laryngitis
  • arthritis
  • side pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • herpes zoster
  • diplopia
  • insomnia
  • weakness
  • angioedema
  • chronic malabsorption syndrome
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • angioedema
  • rhabdomyolysis
  • hair loss
  • itching
  • urticaria
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • dizziness
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • non-cardiogenic pulmonary edema
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture and should be stored in a sealed container. It is best kept at room temperature, neither too hot nor too cold, that is, between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

White round film-coated tablet

Package unit

30 tablets (10 tablets/PTP × 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.